OCD
Conditions
Keywords
sertraline, OCD, fluvoxamine
Brief summary
To verify that sertraline combined with fluvoxamine is superior to sertraline combined with aripiprazole
Detailed description
To verify that sertraline combined with fluvoxamine is superior to sertraline combined with aripiprazole, and to observe the indicators of improving patients' cognitive function and adverse drug reactions, so as to provide evidence-based evidence for supplementing the treatment guidelines for obsessive-compulsive disorder
Interventions
DRUGsertraline fluvoxamine
the initial dose of sertraline was given 50mg/d and the initial dose of fluvoxamine was 50mg/d, and the target dose of sertraline was gradually increased to 200mg/ d and the target dose of fluvoxamine was 200-300mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
DRUGsertraline
The initial dose of sertraline was 50mg/d and the initial dose of aripiprazole was 5mg/d. The target dose of sertraline was 200mg/ d and the target dose of aripiprazole was 5-20mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* The Diagnostic criteria of OCD in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-V), as well as the definition of refractory OCD, are as follows: failure to respond to oral treatment with at least two effective doses of antidepressants, including: Fluoxetine (≥20mg/ d), fluvoxamine (≥200mg/d), sertraline (≥150mg/d), and paroxetine (≥ 40mg/d) were all treated for at least 12 weeks. The Yale-Brown compulsive scale (Y-BOCS) score decreased by \< 35%. * The total score of Yale- Brown compulsion scale (Y-BOCS) ≥16 points. (3)age 12 \ 45 years.
Exclusion criteria
* Exclusion of severe organic brain disease; * Severe physical illness; * Other mental disorders such as tics, disruptive disorders, eating disorders and autism spectrum disorders; * Pediatric streptococcal infection causedby autoimmune neuropsychiatric disease (PANDAS); * Alcohol and drug dependence; Angle-closure glaucoma; * Suicidal tendencies; * Previous history of drug allergies related to research; * Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Y-BOCS score | 12 weeks | Treatment effectiveness was defined as a reduction of ≥35% in Y-BOCS score compared to baseline(12 weeks). Treatment recovery: Y-BOCS score below 8 (12 weeks) |
| Ratio of Y-BOCS score reduction from baseline | 12 weeks | Treatment effectiveness was defined as a reduction of ≥35% in Y-BOCS score compared to baseline(12 weeks). |
Countries
China
Contacts
Primary ContactZheng Lin, Doctor
Outcome results
None listed